Thyrotoxicosis: a rare presentation of molar pregnancy

  1. Eison De Guzman 1,
  2. Hira Shakeel 2 and
  3. Rohit Jain 2
  1. 1 Department of Internal Medicine, The George Washington University Hospital, Washington, District of Columbia, USA
  2. 2 Department of Endocrinology and Metabolism, The George Washington University Hospital, Washington, District of Columbia, USA
  1. Correspondence to Dr Eison De Guzman; icydeg1@gmail.com

Publication history

Accepted:14 Jun 2021
First published:05 Jul 2021
Online issue publication:05 Jul 2021

Case reports

Case reports are not necessarily evidence-based in the same way that the other content on BMJ Best Practice is. They should not be relied on to guide clinical practice. Please check the date of publication.

Abstract

A 49-year-old woman, G8P7, presented with 1 week of worsening vaginal bleeding and abdominal cramps in the setting of a recently discovered unplanned pregnancy. Vaginal ultrasound findings and a significantly elevated human chorionic gonadotropin (hCG) level were concerning for molar pregnancy. She developed signs of hyperthyroidism on the night of admission, for which the endocrinology team was consulted. Laboratory data were consistent with hyperthyroidism. The patient was believed to have thyrotoxicosis secondary to molar pregnancy with concern for impending thyroid storm. Her mental health disorder and bacteraemia made taking care of her further challenging. She was started on a beta-blocker, antithyroid agent and intravenous corticosteroids. She underwent an uncomplicated suction dilation and curettage (D&C), with resolution of her symptoms a few days after. At a follow-up appointment, the patient continued to be asymptomatic and was feeling well.

Background

Molar pregnancy is a relatively rare complication of gestation with an incidence reported in the USA to be 121 per 100 000 pregnancies.1 This complication occurs when there is an abnormal proliferation of trophoblastic tissue, resulting in a non-viable mass that often resembles grape-like structures. The major risk factors for molar pregnancy are prior gestational trophoblastic disease and increased maternal age, especially greater than age 45.1

The most common presenting symptom of molar pregnancy is vaginal bleeding. Hyperemesis gravidarum is a classic association, but presents less frequently than vaginal bleeding.2 An even rarer complication of molar pregnancy is thyrotoxicosis. Although increased thyroid function is often reported in gestational trophoblastic disease, only 5% of these cases show symptoms of hyperthyroidism. It is believed that an elevated hCG level >200 000 IU/L for several weeks is necessary for the development of thyrotoxicosis.3 Treatment is necessary to alleviate the patient’s symptoms and to prevent progression into thyroid storm. Thyroid storm is a lethal condition that, even when treated, has a mortality rate as high as 50%.4

We report a case of molar pregnancy in which the patient subsequently developed thyrotoxicosis. This case highlights the rare complications of molar pregnancy, and the importance of monitoring for clinical hyperthyroidism in this patient population. The case demonstrates how effective treatment of thyrotoxicosis in molar pregnancy not only alleviates the patient’s symptoms, but also helps to prevent progression into the highly lethal thyroid storm.

Case presentation

A 49-year-old woman, G8P7, with asthma and bipolar disorder presented to her primary care provider with nausea, vomiting and bilateral breast tenderness. At the visit, a qualitative urine pregnancy test was positive, revealing an unplanned pregnancy. The patient then began to experience intermittent vaginal spotting that eventually increased to soaking multiple pads throughout the day. This was associated with abdominal cramps that prompted her visit to the emergency room. She had seven uncomplicated vaginal deliveries in the past, the most recent of which was 10 years ago. She has no personal or family history of fibroids, cervical cancer or molar pregnancy.

On admission, the patient was haemodynamically stable with generalised abdominal tenderness on examination. According to her last menstrual period, the estimated gestational age was 15 weeks. She was admitted to the obstetrics and gynecology (OBGYN) team. Later that night, she developed a fever of 39.4°C associated with sinus tachycardia, diaphoresis and tremors in her extremities. On day 2 of admission, she was found to have laboratory data consistent with hyperthyroidism at which point the endocrinology team was consulted.

Investigations

Prior to the endocrinology consultation, the patient underwent a vaginal ultrasound that revealed an enlarged and irregular cystic-appearing endometrium without an intrauterine gestational sac (figures 1 and 2). β-hCG level was disproportionately elevated to 414 600 IU/L given the gestational age. These findings were concerning for molar pregnancy. Her thyroid studies showed an undetectable Thyroid-stimulating hormone (TSH) (<0.015 μIU/mL; first trimester reference range 0.60–3.40), elevated free T4 (3.73 ng/dL; first trimester reference range 0.8–1.2) and elevated free T3 (10.0 pg/mL; first trimester reference range 4.1–4.4). Blood cultures from the day she spiked a fever eventually grew Salmonella species. CT chest/abdomen/pelvis did not reveal a source of the infection, nor did it show evidence of metastases.

Figure 1

Transvaginal ultrasound showing lack of intrauterine sac and abnormal placental tissue with fluid-filled cysts in longitudinal view.

Figure 2

Transvaginal ultrasound showing lack of intrauterine sac and abnormal placental tissue with fluid-filled cysts in transverse view.

Differential diagnosis

The patient’s presentation and workup were consistent with molar pregnancy (nausea, vomiting, vaginal bleeding, ultrasound with no intrauterine sac but with cystic appearance, and significantly elevated hCG). Her laboratory studies showed a new hyperthyroid state (compared with baseline normal Thyroid function tests (TFTs) obtained a few years ago during psychiatric evaluation), and she experienced symptoms of tachycardia, heat intolerance, diaphoresis and tremors. Therefore, the leading differential was thyrotoxicosis secondary to molar pregnancy, as stimulation of TSH receptors by the beta subunit of hCG can cause increased production and release of thyroid hormones.5

Other causes of hyperthyroidism were also considered but deemed less likely clinically. The patient lacked a goitre, pretibial myxoedema, exophthalmos or lid lag to suggest Graves’ disease, although TSH receptor and thyroid peroxidase antibodies were not collected during the admission. She has no history of any thyroid disorders in the family. There was no preceding viral upper respiratory tract infection or neck tenderness to indicate subacute thyroiditis. Fibrinogen was mildly elevated to 558 mg/dL in the setting of concurrent salmonella bacteraemia. In painless (silent) thyroiditis, T4 is usually disproportionately elevated compared with T3, which was the opposite in this case.6 The patient’s home medications were reviewed, and no medications were found that are classically linked to thyroiditis. She does have a history of bipolar disorder, but it has been managed with olanzapine and fluoxetine without prior lithium use. There was no recent iodinated contrast media exposure prior to the development of her symptoms. A thyroid ultrasound was not obtained prior to her emergent intervention.

Infection, such as endometritis, was also on the differential before the blood cultures turned positive, given the fever and tachycardia. Although bacteraemia could explain these abnormal vital signs, it does not account for her other symptoms of heat intolerance and tremors. Besides an enlarged endometrium, the vaginal ultrasound did not show signs of endometritis. The patient also lacked productive cough or dysuria to suggest other infectious aetiologies.

Lastly, the patient had multiple admissions in the past with tachycardia that spontaneously resolved. Her tachycardia then was attributed to excessive caffeine consumption (drinking 4–6 cups of coffee in the morning), as well as frequent use of her albuterol inhaler. However, the patient currently only drinks one cup of coffee a day and has not used her albuterol inhaler in over 2 weeks. She also did not have significant anaemia or decreased urine output to suggest hypovolaemia as a cause of the tachycardia.

Treatment

After reviewing the patient’s case, the endocrinology team reached a consensus that the patient was suffering from thyrotoxicosis secondary to her molar pregnancy. The patient was scheduled for a suction dilation and curettage to evacuate the mole and remove the ultimate source of the β-hCG. On day 2 of admission, she was started on propranolol (not administered due to hypotension) and propylthiouracil (PTU) (500 mg loading dose, followed by 100 mg every 8 hours) to decrease sympathetic hyperactivity and thyroid hormone production, respectively. Although methimazole has a more rapid onset and better side effect profile than PTU, this patient also had significantly elevated free T3 levels, so PTU was chosen for its ability to prevent T4 to T3 conversion.7 After discussion with the OBGYN team, there was initially low suspicion for infection (before blood cultures resulted), so the patient was also started on intravenous hydrocortisone (300 mg loading dose, followed by 100 mg every 8 hours). The decision to start steroids was based on concern of thyroid storm occurring in the perioperative period. At the time the endocrinology team was consulted, the patient had a Burch-Wartofsky Point Scale score of 40, which suggests impending thyroid storm.4 Furthermore, steroids also help decrease conversion of T4 to the more active T3 hormone.8

Overnight, the patient became hypotensive and persistently tachycardic. Due to concerns of sepsis, the OBGYN team performed an emergent suction D&C early on day 3 of admission. Specimen was collecting during the procedure, and pathology revealed diploidy with negative p57 immunohistochemistry stain, consistent with a complete hydatidiform mole.

Outcome and follow-up

After suction D&C, the patient was closely monitored for thyroid storm in the postoperative period, with no worsening of her symptoms. Four days after the procedure, her tachycardia, tremors, diaphoresis and heat intolerance finally resolved. Her thyroid function tests also improved (FT3 3.0 pg/mL, FT4 1.52 ng/dL, TSH 0.016 μIU/mL) (table 1). Her β-hCG level decreased to 14 744 from 414 600 IU/L. Propranolol and PTU were discontinued at that time since the patient was no longer symptomatic. The intravenous steroids were discontinued soon after the procedure due to the patient’s blood cultures turning positive and eventually growing Salmonella species. A CT chest/abdomen/pelvis performed to identify an infectious source was unrevealing. Per discussion with the infectious disease team, the Salmonella bacteraemia was likely secondary to bacterial translocation from the gastrointestinal tract, and the patient was discharged with ciprofloxacin (500 mg two times per day) to complete a 2-week course of antibiotics. She was counselled on molar pregnancy and complications of pregnancy at an advanced maternal age. The importance of contraception use during this postoperative period was emphasised, in order to monitor for a rise in β-hCG that may indicate development of gestational trophoblastic neoplasia (GTN). Imaging is useful not only in diagnosing hydatidiform moles, but also in detecting complications such as GTN metastases, the most common site being the lung.9 In our patient, a chest x-ray and CT chest/abdomen/pelvis did not show any evidence of metastatic disease. Labwork performed 2 weeks after discharge showed continued improvement of her TFTs and β-hCG levels.

Table 1

TFTs and β-hCG (Beta human chorionic gonadotropin) levels

Test Admission value Discharge value 2 weeks postdischarge Reference range
TSH <0.015 0.016 0.249 0.4–4.7 μIU/mL
Free T4 3.73 1.52 1.16 0.70–1.80 ng/dL
Free T3 10.0 3.0 2.9 2.8–5.3 pg/mL
Quantitative β-hCG 414 600 14 744 1060 <10 IU/L (non-pregnant)

Discussion

Molar pregnancy is part of a spectrum of diseases known as gestational trophoblastic diseases. It is a complication defined by abnormal benign or malignant proliferation of trophoblastic cells which result in markedly elevated β-hCG levels. Gestational trophoblastic disease can cause secondary hyperthyroidism as a result of structural homology between β-hCG and TSH. Hormones such as TSH, Follicle-stimulating hormone (FSH), Luteinizing hormone (LH) and hCG are heterodimeric glycoprotein hormones that have an alpha subunit and a beta subunit. The alpha subunit is common to all these hormones. Moreover, there is structural similarity between hCG and TSH beta subunits. Laboratory studies have revealed that normal β-hCG has weak thyrotropic activity on thyroid TSH receptors.10 One unit of β-hCG has the reactivity equivalent to 0.0013 uU of TSH. The level of sialylation of β-hCG determines its bioreactivity on the TSH receptors: the higher the degree of sialylation, the less activity β-hCG will have. The β-hCG produced by hydatidiform moles has greater thyrotropic activity than normal β-hCG due to its decreased sialylation.11 Moreover, the extent of desialylation of β-hCG varies with each molar pregnancy. One unit of β-hCG produced by Gestational trophoblastic disease (GTD) has thyrotropic activity range from 3.72 to 46.8 uU equivalents of TSH.12 It is estimated that for every 10 000 IU/L increase in hCG, there is a 0.1 μIU/mL decrease in TSH and 0.1 ng/dL increase in free T4.13

Increased levels of β-hCG concentration cause a weak hyperthyroid state in a normal pregnancy. The degree of hyperthyroidism is exacerbated by molar pregnancy with elevated levels of β-hCG and decreased levels of sialylation. The extent and development of hyperthyroidism, thyrotoxicosis, and ultimately thyroid storm is determined by multiple factors: the levels of β-hCG, the amount of desialylation, as well as the duration and type of molar pregnancy.

Compared with partial hydatidiform moles, complete hydatidiform moles usually have higher β-hCG levels.14 Therefore, it is not surprising that complete moles have been associated with more severe hyperthyroidism. In one Turkish study, patients with complete moles were found to have significantly lower TSH levels and higher free T4 levels compared with those with partial moles.15 The patients diagnosed with complete moles were also significantly older and of higher gravidity than the patients diagnosed with partial moles. Our patient, who was diagnosed with a complete mole, was 49 years old with seven prior pregnancies. A recent case report describing thyroid storm in a complete molar pregnancy also consisted of an older maternal age woman with multiple pregnancies (G7P3033).16

In the past few decades, physicians have diagnosed molar pregnancies at earlier gestational ages. One Brazilian study found that the average gestational age at time of diagnosis from 1988 to 1992 was 15 weeks, compared with only 10 weeks in 2008–2012.17 This earlier detection is promoted by the increased utilisation of first trimester ultrasound and β-hCG levels for screening of prenatal conditions.18 In our patient, the later diagnosis at 15 weeks gestation was likely due to a delay in seeking medical care after having missed her period.

Treatment of thyrotoxicosis or thyroid storm is based on managing the four major elements involved: the precipitating event; the thyroid gland; the peripheral effects of thyroid hormone and systemic decompensation, if any. The precipitating event in our case was molar pregnancy with the definitive treatment being evacuation. Thyroid hormone synthesis can be curbed with PTU or methimazole, and hormone release can be decrease with iodine. PTU and glucocorticoids can dampen the peripheral effects of thyroid hormone by decreasing the rate of conversion of T4 to the more active T3. Beta blockers, specifically propranolol and esmolol, can decrease the peripheral effects of thyroid hormone by blocking the receptors on which T3 acts. In severe illness, plasmapheresis and charcoal plasma perfusion can help remove excess hormone.19

In our patient, due to active infection, steroids were discontinued after two doses and propranolol was not administered given low blood pressure. She essentially received 5 days of PTU therapy, which was discontinued once her FT4 normalised before discharge. Given that she had suction dilatation and curettage done in an appropriate and timely manner, her thyroid function tests continued to improve following the procedure as did her clinical status.

Patient’s perspective

When I found out I was pregnant, I had no idea about a molar pregnancy. When I realised there was no baby, I was confused. I’ve never had a miscarriage. All my children were live births, so this was strange. I knew something was wrong when I started vomiting so much. I felt like it was killing me. I believe that if I hadn’t come to the doctor, I would have laid in bed and died. I knew I had to come see somebody to find out what was going on with me. I was too sick for a normal pregnancy or even a miscarriage. It took me a while to accept that there was no baby. I was a little sad because I felt like I’ve been punished. Im being honest, I don’t wish this type of pain and illness on anybody. Constantly throwing up, the stomach pain, I don’t want anyone to have to go through this. I want people to know about this disease, so they can avoid what I’ve been through. I am thankful that the surgery went well. I feel that my health is better now. I hope I never experience this again, and that nobody else has to experience it. It’s worse than actually having a baby.

Learning points

  • In patients with molar pregnancies, it is essential to monitor for rare complications such as thyrotoxicosis.

  • Treatment of thyrotoxicosis in molar pregnancies, especially those with significantly elevated β-hCG levels and undetectable TSH levels, is important to prevent progression to thyroid storm.

  • Counselling patients about the risks associated with advanced maternal age pregnancy is necessary for the health of both fetus and mother, and can prevent undesired complications, such as molar pregnancy and thyrotoxicosis in this case.

Ethics statements

Footnotes

  • Contributors EDG, HS and RJ were directly involved in the patient’s care. EDG and HS drafted the manuscript under the supervision of RJ, who provided guidance for the final manuscript. All authors contributed to the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

References

Use of this content is subject to our disclaimer